Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.

Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.

BACKGROUND: Early detection of prostate cancer (PCa) centers on measurements of prostate-specific antigen (PSA), but current testing practices suffer from lack of specificity and generate many unnecessary prostate biopsies. Soluble urokinase plasminogen activator receptor (uPAR) is present in blood...

Full description

Bibliographic Details
Main Authors:	Piironen, T, Haese, A, Huland, H, Steuber, T, Christensen, I, Brünner, N, Danø, K, Høyer-Hansen, G, Lilja, H
Format:	Journal article
Language:	English
Published:	2006

Similar Items

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
by: Nurmikko, P, et al.
Published: (2002)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
by: Steuber, T, et al.
Published: (2007)

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
by: Steuber, T, et al.
Published: (2002)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
by: Haese, A, et al.
Published: (2001)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
by: Haese, A, et al.
Published: (2003)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
by: Haese, A, et al.
Published: (2003)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
by: Steuber, T, et al.
Published: (2005)

[Isoforms of free prostate-specific antigen]
by: Haese, A, et al.
Published: (2004)

Isoforms of free prostate-specific antigen
by: Haese, A, et al.
Published: (2004)

Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
by: Kjellman, A, et al.
Published: (2011)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
by: Becker, C, et al.
Published: (2000)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
by: Nurmikko, P, et al.
Published: (2001)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
by: Haese, A, et al.
Published: (2004)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
by: Haese, A, et al.
Published: (2000)

Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA.
by: Nurmikko, P, et al.
Published: (2000)

Serum markers for prostate cancer: a rational approach to the literature.
by: Steuber, T, et al.
Published: (2008)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues.
by: Cao, Y, et al.
Published: (2003)

Prediction of tumor heterogeneity in localized prostate cancer.
by: Huland, H, et al.
Published: (2002)

Circulating biomarkers for prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
by: Becker, C, et al.
Published: (2000)

A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
by: Valtonen-André, C, et al.
Published: (2007)

Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues.
by: Bjartell, A, et al.
Published: (2000)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
by: Haese, A, et al.
Published: (2003)

Evaluation of automatic discrimination between benign and malignant prostate tissue in the era of high precision digital pathology
by: Yauheniya Zhdanovich, et al.
Published: (2023-01-01)

Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
by: Sofia C. Nunes, et al.
Published: (2023-09-01)

Serum laser Raman spectroscopy as a potential diagnostic tool to discriminate the benignancy or malignancy of pulmonary nodules
by: Huaichao Luo, et al.
Published: (2023-05-01)

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma
by: Ourania S. Kotsiou, et al.
Published: (2022-10-01)

Is serum prostate-specific antigen a diagnostic marker for benign and malignant breast tumors in women?
by: Seyed Hasan Emami Razavi, et al.
Published: (2015-01-01)

Ultrasonographic Discrimination of Benign and Malignant Breast Lumps with Histopathological Correlation
by: Tarana Yasmin, et al.
Published: (2015-09-01)

Computational pathology to discriminate benign from malignant intraductal proliferations of the breast.
by: Fei Dong, et al.
Published: (2014-01-01)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
by: Siivola, P, et al.
Published: (2000)

Elevated plasma urokinase receptor predicts low birth weight in maternal malaria.
by: Ostrowski, SR, et al.
Published: (2007)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
by: Haese, A, et al.
Published: (2005)

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
by: Aalamian, M, et al.
Published: (2003)

Androgen Receptor Roles in Benign and Malignant Prostate Disease
Published: (2011-06-01)

The study of mucin histochemistry in benign and malignant lesions of prostate
by: Durgaprasad N Agrawal, et al.
Published: (2014-01-01)